Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Delayed hypersensitivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Delayed hypersensitivity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-003019-39 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:
    Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study
    Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001738 Allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004391-11 Sponsor Protocol Number: RCC-DC-2011 Start Date*: 2012-02-08
    Sponsor Name:Masaryk University
    Full Title: Treatment of metastatic renal cell carcinoma using interleukin-12 secreting dendritic cells. Phase I/II clinical trial.
    Medical condition: Metatastic renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001232-27 Sponsor Protocol Number: KLHExposure Start Date*: 2012-06-04
    Sponsor Name:Charité Universitaetsmedizin Berlin
    Full Title: Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001537-92 Sponsor Protocol Number: RHMCHI0714 Start Date*: 2014-07-02
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 study
    Medical condition: Children aged 24 months to (and including) 17 years with IgE-mediated food allergy to egg protein
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004870 10014315 Egg allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002031-26 Sponsor Protocol Number: RHMCHI065 Start Date*: 2013-06-25
    Sponsor Name:University Hospitals Southampton NHS Foundation Trust
    Full Title: Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE study
    Medical condition: Children aged 24 months to (and including) 17 years with IgE-mediated food allergy to egg protein
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10014315 Egg allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000727-42 Sponsor Protocol Number: CYT004-MelQbG10 01 Start Date*: 2006-01-20
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A-VLP Vaccine in HLA-A2 Positive Patients with stage III/IV Malignant Melanoma
    Medical condition: Patients with Stage III/IV Malignant Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013406-13 Sponsor Protocol Number: GBM-DC-2009 Start Date*: 2009-10-07
    Sponsor Name:Masaryk University
    Full Title: First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study...
    Medical condition: Glioblastoma Multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003420-38 Sponsor Protocol Number: PPD1 Start Date*: 2007-12-28
    Sponsor Name:Umeå University
    Full Title: The effect of Rapydan lidocain/tetracain patch on pain-response and reproducibilty in Tuberculin test
    Medical condition: Pain response to intradermal injection of tuberculin.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064882 Procedural pain LLT
    9.1 10044726 Tuberculin test LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000712-42 Sponsor Protocol Number: IOM-115 Start Date*: 2004-12-22
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: Enhacement of the lower extremities computed tomography: IOMERON®-400 VS VISIPAQUE™-320 (ELECTIV).
    Medical condition: subjects with mild to moderate renal impairment (SCr =1.5-2.5 mg/dL and/or calculated CrCl = 10-60 mL/min) who undergo clinically-indicated IV contrast-enhanced MDCTA scanning of the lower extremit...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000711-26 Sponsor Protocol Number: IOM-114 Start Date*: 2004-12-22
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: ABDOMINAL COMPUTED TOMOGRAPHY: IOMERON®400 VS VISIPAQUE™320 ENHANCEMENT (ACTIVE).
    Medical condition: subjects with mild to moderate renal impairment scheduled to undergo clinically-indicated IV contrast –enhanced MDCT scanning of the liver
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000084-32 Sponsor Protocol Number: CHDR1701 Start Date*: 2017-02-16
    Sponsor Name:Centre for Human Drug Research
    Full Title: A study to characterize the humoral and cellular response following simultaneous immunization with a neo-antigen (KLH) and a recall antigen (tetanus) in healthy volunteers
    Medical condition: Immune response
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004527-23 Sponsor Protocol Number: MM1636 Start Date*: 2017-03-14
    Sponsor Name:Center for Cancer Immune Therapy
    Full Title: Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine with Montanide to patients with metastatic malignant melanoma
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000795-15 Sponsor Protocol Number: MYVAC2 Start Date*: 2014-01-29
    Sponsor Name:UZ Brussel
    Full Title: An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after f...
    Medical condition: Symptomatic Multiple Myeloma after first-line autologous stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002357-35 Sponsor Protocol Number: CRO1959 Start Date*: 2012-10-23
    Sponsor Name:Imperial College London
    Full Title: Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003532-68 Sponsor Protocol Number: FIBCON Start Date*: 2014-03-11
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: Fibrinogen concentrate supplementation in the management of bleeding during paediatric cardiopulmonary bypass: a phase 1B/2A, open label dose escalation study (Version 1.0, Jan 28, 2014)
    Medical condition: Neonates and infants who are at risk of mediastinal bleeding following cardiopulmonary bypass surgery for congenital heart disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10055817 Haemorrhage intrapericardial LLT
    16.1 100000004850 10010495 Congenital heart disease NOS LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005740-83 Sponsor Protocol Number: 4825 Start Date*: 2007-01-12
    Sponsor Name:University of Southampton
    Full Title: A Pragmatic Randomised Trial of Ibuprofen, Paracetamol, Steam and Delayed Prescribing for Patients with Respiratory Tract Infections in Primary Care
    Medical condition: Inclusion criteria Patients aged 3 to 65 presenting to a GP or nurse with an RTI (acute cold, influenza, sore throat, otitis media, sinusitis, croup, or lower respiratory tract infection). Exclus...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024970 Respiratory tract infections HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005731-67 Sponsor Protocol Number: NLxxxxxxxxxx Start Date*: 2021-07-02
    Sponsor Name:Haaglanden Medisch Centrum
    Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Subarachnoid Hemorrhage - A phase II trial on the safety and efficacy of C1 esterase inhibitor for the acute management of subar...
    Medical condition: Subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002567-24 Sponsor Protocol Number: M120204-063 Start Date*: 2005-04-04
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis
    Medical condition: The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000424-10 Sponsor Protocol Number: UC-0130/1703 Start Date*: 2017-06-16
    Sponsor Name:UNICANCER
    Full Title: A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN).
    Medical condition: Patients with recurrent and/or metastatic platinum refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN), with poor prognosis and no effective chemotherapy options.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 11:47:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA